Company Aggregate Debt: ESSA Pharma, Inc. (EPIX)

ESSA Pharma Inc. (EPIX) maintains a debt profile that allows it to filter out market noise, where the 0.00 mark serves as a relevant indicator. Borrowing dynamics correlate with molecule selectivity and grant support within the oncology ecosystem. Operational flexibility is ensured through the outsourcing of production to US-based CMO facilities. In the long term, a unique approach to prostate receptors will create the conditions for pricing power in therapy.

Company Aggregate Debts: ESSA Pharma Inc. (EPIX) for 07/04/2022 - 10/25/2025

Analytical breakdowns and data insights for company ESSA Pharma Inc. (EPIX)

- price and consensus price forecast:

Stock Price essapharma.com|EPIX - Price Target Chart

- market capitalization data:

Market Capitalization ESSA Pharma Inc|EPIX - Enterprise Value

- book capitalization data:

Accounting Value per Share ESSA Pharma|EPIX - Book Capitalization|Market-to-Book Ratio essapharma.com|EPIX - Aggregate Company Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio ESSA Pharma Inc.|EPIX - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital essapharma.com|EPIX - Company Total Debt|Debt to Book Value ESSA Pharma Inc

Summary company analytics:ESSA Pharma, Inc. EPIX

Managing debt load is critical for assessing the financial stability of the biotechnology sector while minimizing default risks. For ESSA Pharma Inc. (EPIX), with its focused team of oncology experts, this parameter reflects the funding efficiency of clinical trials. The total volume of all liabilities, through the debt trend, allows for an assessment of the balance between borrowed capital and the investment potential for business development.

Competitor analysis for ESSA Pharma Inc.